Multi-branched ionic liquid-chitosan as a smart and biocompatible nano-vehicle for combination chemotherapy with stealth and targeted properties

Rahimi, Mahdi; Shafiei‐Irannejad, Vahid; Safa, Kazem D.; Salehi, Roya

doi:10.1016/j.carbpol.2018.05.059

Cited by 62 publications

(34 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 26 Therefore, the changes in particle size of NLC/D-S were monitored for 48 h. As displayed in Figure 1 B, NLC/D-S showed almost no changes in size in both media, which suggested that NLC/D-S might be able to maintain stability upon in vivo applications, which was a primary requirement for drug delivery in cancer therapy. 19 , 27 …”

Section: Resultsmentioning

confidence: 99%

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

The tumor microenvironment (TME) plays a significant role in weakening the effect of cancer immunotherapy, which calls for the remodeling of TME. Herein, we fabricated a nanostructured lipid carrier (NLC) to codeliver doxorubicin (Dox) and sorafenib (Sfn) as a drug delivery system (NLC/D-S). The Sfn was expected to regulate the TME of esophagus cancer. As a result, the immune response induced by Dox-related immunogenicity cell death could be fully realized. Our results demonstrated that Sfn was able to remodel the TME through downregulation of regulatory T cells (Treg), activation of effector T cells, and relieving of PD-1 expression, which achieved synergistic effect on the inhibition of primary tumor but also subsequent strong immune response on the regeneration of distant tumor.

show abstract

Section: Resultsmentioning

confidence: 99%

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Various NP surface coatings have been investigated to reduce protein adsorption and subsequently increase circulation time, the most common including polymers such as polyethylene glycol (PEG) [135][136][137], polysaccharides [138], and zwitterions [139,140]. To date, PEGylation continues to be a dominant strategy in increasing circulation times of MNPs, such as in magnetic particle imaging (MPI).…”

Section: Magnetic Nanoparticles: Toxicity Biodistribution Pharmacokmentioning

confidence: 99%

Recent Advancements of Magnetic Nanomaterials in Cancer Therapy

2020

View full text Add to dashboard Cite

Magnetic nanomaterials belong to a class of highly-functionalizable tools for cancer therapy owing to their intrinsic magnetic properties and multifunctional design that provides a multimodal theranostics platform for cancer diagnosis, monitoring, and therapy. In this review article, we have provided an overview of the various applications of magnetic nanomaterials and recent advances in the development of these nanomaterials as cancer therapeutics. Moreover, the cancer targeting, potential toxicity, and degradability of these nanomaterials has been briefly addressed. Finally, the challenges for clinical translation and the future scope of magnetic nanoparticles in cancer therapy are discussed.

show abstract

“…In spite of the fact that chemotherapy is the major and effective therapeutic strategy in cancer, emergence of resistance in tumor cells against chemotherapeutic agents is a big obstacle and main disadvantage of this strategy. 5 Because of the involvement of multiple factors in the development of two types of MDR, innate and acquired phenotypes, an exact understanding of the molecular mechanisms has critical importance in the development of effective treatment modalities. Until now, the well-understood mechanism of MDR is related to the resistance developed by the overexpression of the members of the ATP-binding cassette (ABC) membrane transporter superfamily with 48 identified genes.…”

Section: Potential Mechanisms Of Mdrmentioning

confidence: 99%

Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons

Majidinia

Mirza-Aghazadeh-Attari

Rahimi

et al. 2020

IUBMB Life

Self Cite

120

View full text Add to dashboard Cite

Multidrug resistance (MDR), defined as the ability of cancer cells to gain resistance to both conventional and novel chemotherapy agents, is an important barrier in treating malignancies. Initially, it was discovered that cellular pumps dependent on ATP were the cause of resistance to chemotherapy, and further studies have found that other mechanisms such as increased metabolism of drugs, decreased drug entry, and defective apoptotic pathways are involved in this process. MDR has been the focus of numerous initiatives and countless studies have been undertaken to better understand MDR and formulate strategies to overcome its effects. The current review highlights various nano‐drug delivery systems including polymeric/solid lipid/mesoporous silica/metal nanoparticles, dendrimers, liposomes, micelles, and nanostructured lipid carriers to overcome the mechanism of MDR. Nanoparticles are novel gateways to enhance the therapeutic efficacy of anticancer agents at the target site of action due to their tumor‐targeting abilities, which can limit the unwanted systemic effects of chemotherapy agents and also reduce drug resistance. Additionally, other innovative strategies including RNA interference as a biological process used to inhibit or silence specific gene expression, natural products as MDR modulators with little systemic toxic effects, which interfere with the functions of proteins involved in drug efflux, and physical approaches such as combination of conventional drug administration with thermal/ultrasound/photodynamic strategies are also highlighted.

show abstract

Multi-branched ionic liquid-chitosan as a smart and biocompatible nano-vehicle for combination chemotherapy with stealth and targeted properties

Cited by 62 publications

References 40 publications

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

Recent Advancements of Magnetic Nanomaterials in Cancer Therapy

Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons

Contact Info

Product

Resources

About